Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cytogenix interviews and articles.
[misc.invest.stocks]
Subject: Cytogenix interviews and articles.
From: cygx links
Newsgroups: misc.invest.stocks
Date: Apr 18 2004 09:23:14
Here's an archive of important links re: CYGX, a very small biotech
company that can generate ssDNA inside mammalian cells. How
revolutionary is this? Their patented fundamental technology could
possibly cure sepsis (250,000 deaths a year); herpes (1 in 4 are
infected); various inflammatory conditions like acne, bedsores,
psoriasis and joint swelling; rhinovirus (common cold); human
papilloma virus (cause of cervical cancer); various cancers; fungus;
and E. coli, strep and staph bacterial infections (without causing
resistance); even pattern baldness. All told, these markets are in
the tens of billions. Sounds completely unbelievable? Some of the
world's leading scientists are on the BOD and scientific advisory
board. An ex-Oracle Sr. VP and world leading patent authority is also
on BOD. So far: 99% herpes viral load reduction in cell cultures and
animals. 100% survival rate for septic mice. Very encouraging early
results against lung cancer. Work also proceeding against solid
tumors and melanoma. CEO believes 2004 will be breakout year.
Presently in talks for 3-4 years of financing, to greatly expand
efforts. This technology is proven to work, it's just a matter of
delivery into target cells. This technology can be applied to the 800
or so antisense molecules developed in past years by numerous biotech
companies. The CYGX technology generates millions of these molecules
INSIDE LIVING CELLS. Listen to the most recent interviews.
http://www.geocities.com/cygx_links/
Arnold, I see the glass half full.EOM
We should be hearing about some grant money news soon.
Dr. Frederic Kendirgi, now completing Post Doctoral studies at Vanderbilt University has accepted our offer to join our staff as of October 1, 2004. Dr. Kendirgi received his Ph.D. in Biochemistry and Molecular Biology at the University of Calgary and has developed broad experience in Virology/Immunology, assays for protein function and expression vector applications.
Our latest federal government supported, Small Business Innovation Research (SBIR) grant application entitled, "Bactericidal PEGylated Peptide-PNA Conjugate" has been received by the National Institutes of health and has been assigned to the Center for Scientific Review Special Emphasis Panel. The grant application will be reviewed in November 2004. The SBIR grant entitled, "Generation of DNA enzyme using adenoviral vectors" submitted in April, 2004, has received the first cycle review and awaits funding decisions on the April round of grant submissions
Woodrow ,I think it was PP trying to show that theywere doing something but in reality it was smoke and mirrors on PP part.It also could have been a self serving PR to have some ammo for the pending law suit,to show the judge that PP were on top of things.I also think that CYGX was a little glad that PP was screwing up and that they were not making progress ,at one point CYGX must have sat down and realized that the India ,China deal was a bad move for a few reasons,one,technology theft,and two,FDA frowning on CYGX for such a move.
archinla that is a standard statement for all BB otc companys ,they all use that one on 10QSB .Tell your friend To buy when financing happens if he is troubled to buy now, but also tell him when that happens he may have to pay a lot more for the stock.Also did he go to Cytogenix website ,lots of good DD there.
BigB You know and I know that the share price shouldn't have move down with this low volume the Market Makers are trying to build up their supply of CYGX on cheap shares and trying to cause a slide in the process.
Peace I hope they don't settle.I hope they use Mr.Ocampo experience and show the world that Cytogenix is a force to be dealt with ,so that future licensees will know they can't walk all over CYGX with out paying a price .
Yes real die hard longs ,If you think the Market Makers are short now wait for the good news to hit this will rocket .
Clearly PP ran with the ball and dropped it, I don't see how CYGX management is at falt.
Thank you arnold for posting CYGX side of the suit .It does look like Cytogenix has a strong case, but like you said lets keep and open mind.Thanks
Nigel I was going to hire you for my butler , but now you will have to continue your career at Burger King.Its best to keep your mouth shut and give an impression of stupidity than opening it and confirming it ,Nigel your confirmation has been received completely.
Lets hope that just one of the customers is a heavy hitter.The word of Cytogenix technology will spread like wild fire .
Vol. 3, No. 6 Monday: November 15, 2004 e-street journal
Unsubscribe Company Profiles; Acorns to Oaks
education
editorials
21st Century Medicine: Genetic therapy promises dramatic change from treating symptoms to eliminating the disease
"Things are only impossible until they're not."
-- Jean-Luc, Star Trek, The Next Generation
"Our increasing understanding of the mechanisms of conversion of the genetic code into function indicates that gene based therapy will become a mainstay of disease control in the 21st century." O. Michael Colvin, Duke University Medical center.
"Every person", says Dari Shalon, Director of the Center of Genomics Research at Harvard University, "has 100,000 genes but some will malfunction, creating diseases. Through gene therapy," Professor Shalon continues. "a gene can be altered and a disease or condition can be treated."
One emerging company, CytoGenix,Inc.(CYGX) promises to have an impressive impact on medicine in the 21st century. Founded in 1995, the Company owns U.S. and foreign patents for a gene regulation technology that has been shown to be effective in targeting and reducing gene expression and providing potentially therapeutic agents for the treatment of human and animal diseases.
CytoGenix has developed Antisense and DNA enzymatic systems to "turn off" proteins involved in Herpes Simplex, Inflammation and Alopecia (pattern baldness). Anecdotal results have shown: Prevention of herpes lesions. Decrease in frequency of herpetic lesions. Growth of hair on male scalps which had been previously bald. Decrease in size and severity of Psoriasis lesions.
"Genetic Activity is at the root of virtually all disease states." says renowned researcher and Vice President of CYGX, Dr Yin Chen. "Genetically based therapies," Dr. Chen continues, "have the potential to shift the emphasis of healthcare from palliative to prevention; that is, from simply treating symptoms to actually eliminating disease."
The magic bullet. Modern medicine has found ways to send signals to the body's DNA to alter a structure that is either malfunctioning or failing to function at maximum potential. Hundreds of these so-called magic bullets have been designed; some by other companies. The problem, to date, has been finding a way to get the bullet quickly, efficiently and in sufficient quantity to the gene in need of change. CytoGenix has solved this important problem with their patented, proprietary technology. It is this technology that may enable CYGX to capture a significant share of a massive market in the USA and the world.
CYGX has management team uniquely equipped to capture a significant share of this vast market. Leading the team, CEO Malcolm Skolnick, a registered patent attorney and a PhD in physics, offers unique skills and experience as a researcher conducting clinical trials, as a patented inventor, as a former chairman of a NIH study section and as licensing officer for the University of Texas Health Science Center at Houston. On the team, in addition to other outstanding researchers and financial experts is Dr.Yin Chen who is one of the co-inventors of CytoGenix's proprietary ssDNA system technology. A scientific advisory board assists the management team.
Scientific Advisory Board. The Scientific Advisory Board reviews and critiques data when the company seeks scrutiny and verification of pertinent scientific/technical matters. This prestigious board includes respected academic physicians, and internationally recognized researchers in some of America's leading universities. The Company enters the market with confidence.
"We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
Commercial opportunities for gene therapy. CEO Skolnick, points out some of the many areas where gene therapy can make a major contribution: Therapeutics. the extreme specificity of gene therapy offers real therapeutic promise for cancer and viral infections .Anti-viral drugs and vaccines are estimated to be about a third of the approximately $7 billion spent worldwide on anti-infectives last year. For aids alone the statistics are staggering. The Centers for Disease Control estimate that in the United States 1 to 1.5 million people are infected with HIV. Agriculture The use of gene therapy to develop agricultural animals or crops that are resistant to viruses or other diseases has considerable commercial significance. In the United States, for example, it is estimated that viruses are responsible for the loss of $1.5 to $2 billion in crop value each year. Bioprocessing industry The cost of failed drug discovery is the biggest drain on pharmaceutical profits. A recent industry study estimates the cost of developing a new drug at $880 million, and 75% of this cost is due to failed drugs. CytoGenix anticipates that pharmaceutical companies will welcome the fast turnaround Target Validation service CYGX can provide. The total Target Validation market is now worth $200-$500 million and will grow at the rate of 30% annually the next ten years.
As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
"It's not what you look at that matters, It's what you see."
-- Henry David Thoreau
Perhaps when you look at CYGX you will see
that it has an important place in your portfolio
www.cytogenix.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Statements in these newsletters regarding any company's reported business that are not historical facts are "forward-looking statements" that involve risk and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the company's Annual Report or Form 10k for the most recently ended fiscal year.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED WRITTEN CONSENT OF THE EDITORS OF THE E Street Journal.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and or the National Association of Securities Dealers (NASDAQ) at www.nasd.com
Vol. 3, No. 6 Monday: November 15, 2004 e-street journal
Unsubscribe Company Profiles; Acorns to Oaks
education
editorials
21st Century Medicine: Genetic therapy promises dramatic change from treating symptoms to eliminating the disease
"Things are only impossible until they're not."
-- Jean-Luc, Star Trek, The Next Generation
"Our increasing understanding of the mechanisms of conversion of the genetic code into function indicates that gene based therapy will become a mainstay of disease control in the 21st century." O. Michael Colvin, Duke University Medical center.
"Every person", says Dari Shalon, Director of the Center of Genomics Research at Harvard University, "has 100,000 genes but some will malfunction, creating diseases. Through gene therapy," Professor Shalon continues. "a gene can be altered and a disease or condition can be treated."
One emerging company, CytoGenix,Inc.(CYGX) promises to have an impressive impact on medicine in the 21st century. Founded in 1995, the Company owns U.S. and foreign patents for a gene regulation technology that has been shown to be effective in targeting and reducing gene expression and providing potentially therapeutic agents for the treatment of human and animal diseases.
CytoGenix has developed Antisense and DNA enzymatic systems to "turn off" proteins involved in Herpes Simplex, Inflammation and Alopecia (pattern baldness). Anecdotal results have shown: Prevention of herpes lesions. Decrease in frequency of herpetic lesions. Growth of hair on male scalps which had been previously bald. Decrease in size and severity of Psoriasis lesions.
"Genetic Activity is at the root of virtually all disease states." says renowned researcher and Vice President of CYGX, Dr Yin Chen. "Genetically based therapies," Dr. Chen continues, "have the potential to shift the emphasis of healthcare from palliative to prevention; that is, from simply treating symptoms to actually eliminating disease."
The magic bullet. Modern medicine has found ways to send signals to the body's DNA to alter a structure that is either malfunctioning or failing to function at maximum potential. Hundreds of these so-called magic bullets have been designed; some by other companies. The problem, to date, has been finding a way to get the bullet quickly, efficiently and in sufficient quantity to the gene in need of change. CytoGenix has solved this important problem with their patented, proprietary technology. It is this technology that may enable CYGX to capture a significant share of a massive market in the USA and the world.
CYGX has management team uniquely equipped to capture a significant share of this vast market. Leading the team, CEO Malcolm Skolnick, a registered patent attorney and a PhD in physics, offers unique skills and experience as a researcher conducting clinical trials, as a patented inventor, as a former chairman of a NIH study section and as licensing officer for the University of Texas Health Science Center at Houston. On the team, in addition to other outstanding researchers and financial experts is Dr.Yin Chen who is one of the co-inventors of CytoGenix's proprietary ssDNA system technology. A scientific advisory board assists the management team.
Scientific Advisory Board. The Scientific Advisory Board reviews and critiques data when the company seeks scrutiny and verification of pertinent scientific/technical matters. This prestigious board includes respected academic physicians, and internationally recognized researchers in some of America's leading universities. The Company enters the market with confidence.
"We know our ssDNA expression system works." said CEO Skolnick," The proof of concept phase is over. We are now ready to develop our broad-based technology into important therapeutics to eliminate or ameliorate specific disorders."
Commercial opportunities for gene therapy. CEO Skolnick, points out some of the many areas where gene therapy can make a major contribution: Therapeutics. the extreme specificity of gene therapy offers real therapeutic promise for cancer and viral infections .Anti-viral drugs and vaccines are estimated to be about a third of the approximately $7 billion spent worldwide on anti-infectives last year. For aids alone the statistics are staggering. The Centers for Disease Control estimate that in the United States 1 to 1.5 million people are infected with HIV. Agriculture The use of gene therapy to develop agricultural animals or crops that are resistant to viruses or other diseases has considerable commercial significance. In the United States, for example, it is estimated that viruses are responsible for the loss of $1.5 to $2 billion in crop value each year. Bioprocessing industry The cost of failed drug discovery is the biggest drain on pharmaceutical profits. A recent industry study estimates the cost of developing a new drug at $880 million, and 75% of this cost is due to failed drugs. CytoGenix anticipates that pharmaceutical companies will welcome the fast turnaround Target Validation service CYGX can provide. The total Target Validation market is now worth $200-$500 million and will grow at the rate of 30% annually the next ten years.
As part of the important Drug Target Validation Service, CYGX is the sole pioneer in developing novel business structures to effectively combine leading edge biotechnology with traditional pharmacology through PharmaGenix, LLC, a joint enterprise with the Professional Compounding Centers of America, and their nearly 3,000 member compounding pharmacists.
It may well be that many previously incurable diseases will be cured through the gene therapy. CytoGenix, Inc. will play a vital role in this effort because of the insight of the company's leadership. CEO Malcolm Skolnick understands and agrees with an observation made long ago:
"It's not what you look at that matters, It's what you see."
-- Henry David Thoreau
Perhaps when you look at CYGX you will see
that it has an important place in your portfolio
www.cytogenix.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Statements in these newsletters regarding any company's reported business that are not historical facts are "forward-looking statements" that involve risk and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the company's Annual Report or Form 10k for the most recently ended fiscal year.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED WRITTEN CONSENT OF THE EDITORS OF THE E Street Journal.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and or the National Association of Securities Dealers (NASDAQ) at www.nasd.com
Ecmorgan I just went to the target validation service at Cytogenix website see clause at bottom.
Results
CytoGenix adheres to GLP quality standards and will provide complete experiment documentation including quantitative mRNA and protein expression data.
Turnaround
CytoGenix scientists will consult with the client's scientists to establish optimum conditions. The goal is to achieve a six (6) week turnaround for genes expressed in commonly used cell lines.
Terms and Conditions
Target Validation services are provided under a Service contract that includes mutual confidentiality clauses. CytoGenix proprietary technology will be used to provide gene target information only. Any other use by CytoGenix or the client is subject to other arrangements
Peace it would be nice to find out which companies they are working with ,but A non disclosure clause must have been signed with them.We can hope that the people involved will tell their friends and get the word out about Cytogenix.
renshen1 level 2 shows buys and sells. Ask an bid are always changing during the day ,MM's lowered the ask at the end of the day from.295 cents to.29 even thought it was all buys the last 30 minutes ,it doesn't make sense to us ,you would think that they would want to make as much money as possible but the MM's are smart in the ways of trying to shake the tree for shares ,trying to give the feel that the price is on a down trend which they artificially created,although today had a 1 sell to 1 buy ratio it should not have gone down.Same thing they did to AIDO .
last half hour all BUYS as I Thought ,one sell 4 minutes after hours 2000 shares at .27 just so it will look like we ended on the low.A little tree shaking today .MM"s up to their old tricks.Just think MM's drove the stock down 15% in three days with low trading at about .02% of the float trading we all know that is not wright.
Howardjoel how or why two different versions of sec filling
scmorgan were in the PR is "without merit" I just can't find it.
This is interesting CYGX is conducting a pilot studies for several companies ? Wow that sounds good.
Genomics field has expanded the number of potential drug targets to several thousand. The CytoGenix proprietary gene down-regulation system is a powerful tool in confirming gene target function. In July 2002, we inaugurated a service geared towards assisting pharmaceutical and biotech companies improve drug discovery efficiency. In addition to our work on in-house targets, we are conducting a pilot studies for several companies. For a fixed fee, we will knockdown a gene in a cell system. This will confirm the gene's relevance to the disease of interest. Those genes found to be highly disease-related become targets for new drug or molecular therapies
accumulation should happen at the end of trading day,about half hour before 4 oclock.
Skoobyfl1 I think a quiet accumulation has been happening for a few weeks now and if my hunch is correct we should see a nice jump in share price this week .I also think that a PR is due on the following ,Baylor College test results , grant money, a new patent, a new hire , funding.
arnold you didn't study it thoroughly ,your words ,and you don't have the pages where CYGX answered the lawsuit , but boldly you proclaim Hogger's summary is accurate.WOW .Hogger's summary might be accurate ,but not by your reasoning. Lets just say that Hogger might have over look something and we will wait and see.Let hope that Tatonkano62 can get the full verson of the law suit and see what he thinks.
specul8 another quiet accumulation day again last 15 minutes three big blocks of 10,000 shares went through ,All I can think of is the people at baylor are buying because the results are very promising with the lung cancer trials and those people tell their friends and relatives and good news is spreading.It is very hard to keep the good news from getting out. I could be wrong but I am feeling there is good news around the corner.
sukycospito just reread this post from the last news PR, CYGX is a volcano ready to explode the science is incredible ,also if I hurt you with my joke I am sorry .
Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "We believe that the CY401 compound is highly effective against a wide range of human pathogenic bacteria strains including the most resistant. Results achieved to date support this premise. Planned additional experiments will further demonstrate that this compound effectively addresses a significant unmet medical need."
"An important feature of CY401 is that it was designed to target genes that are absolutely essential to the existence of most bacteria. For this reason, the bacteria cannot become resistant by mutating this gene because any change will result in its death," adds Dr. Skolnick.
Sukycospito you must know I was joking ,you got to admit it was a little funny.Hay if I did't like you I wouldn't have joke with you .Have a good night all see ya tomorrow night.
grrdvm1 You really think that Merck is toast ,they are a billion dollar company .They have 2.20 billion shares out at around 24 dollars a share 4.71 billion dollars in profit.I think they will take a hit but I don't think its a knock out punch.
If we could email Dr. CHARLES L. Densmore and ask how the study went.
Kinsey B, Densmore C, Orson F. (2004). Gene delivery to the lungs by polycations. Polymeric Gene Delivery: Principles and Applications. Edited by M. M. Amiji. (In Press)
Kinsey B, Densmore C, Orson F. (2004). Non-Viral Gene Delivery to the Lungs. Current Gene Therapy. (accepted).
Telephone: (713) 798-3603
Fax: (713) 798-3475
E-mail: charlesd@bcm.tmc.edu
I wonder if Baylor College as finished this study
news / People in the news
LATEST NEWS
January 21, 2004
Researchers team to study spread of lung cancer
A biopharmaceutical company and a medical school have teamed up to see how effective a gene delivery system can stop lung cancer from spreading in mice.
Houston-based CytoGenix Inc. has entered into an agreement with scientists at Baylor College of Medicine to conduct experiments using a combination of the company's DNA expression vector technology and Baylor's proprietary aerosol gene delivery technology.
The combination is designed to silence a gene that in turn will keep the cancer from spreading.
Silencing, or knocking down, a gene is a technique that turns off a specific gene to see how it functions.
Charles L. Densmore, assistant professor of Baylor College of Medicine's department of molecular physiology and biophysics, will direct these studies to determine the effect this gene delivery and silencing system has on cancer in the lungs of mice. He invented the aerosol gene delivery system and has pioneered its use for lung cancer, asthma and other pulmonary disorders.
According CytoGenix Chairman and CEO Malcolm Skolnick, metastatic lung tumors are important targets because several cancers such as melanoma breast and prostate tend to spread, or metastasize, in the lungs.
CytoGenix develops and markets products and services based on its core DNA expression technology.
Hanuman My Aunt would get cortizone treatments injected in her knee every month ,I don't see why Cytogenix couldn't inject the SSDNA directly into the arthritic area .PS don't know if cortizone is spelled correctly.
Green Acres that was a very good post hope to hear from you more often.Thanks
I think you are correct.
Copyright © 2004 C3 Entertainment, Inc. All rights reserved.
The Three Stooges®, characters, and all related indicia are trademarks of C3 Entertainment, Inc.
Inflammatory Disorders
Errant inflammatory response cause many human disorders and conditions. These include the formation of atherosclerotic plague the leads to heart attacks or stroke and rheumatoid arthritis. The biochemical process or "cascade" of inflammation is varied and very complex. Scientists have found common proteins and expression of certain genes in many of these inflammatory reactions. The Company has applied its technology to silence a powerful inflammation-causing gene and, has applied this sequence to a topical formulation against several inflammatory skin conditions.
Psoriasis Topical Therapeutic
The National Institutes of Health report, "Psoriasis is a chronic (long-lasting) skin disease of scaling and inflammation that affects 2 to 2.6 percent of the United States population, or between 5.8 and 7.5 million people. Although the disease occurs in all age groups, it primarily affects adults. It appears about equally in males and females. Psoriasis occurs when skin cells quickly rise from their origin below the surface of the skin and pile up on the surface before they have a chance to mature." -- http://www.niams.nih.gov/hi/topics/psoriasis/psoriafs.htm
Psoriasis is an immune system disorders that triggers an inflammatory response. CytoGenix scientists are developing a topical cream containing the company's proprietary ssDNA expression system engineered to express a sequence that silences a human gene associated with most inflammation.
The Company has scheduled initial preclinical studies to commence in 3rd quarter 2004.
Contact Dermatitis Topical Therapeutic
Eczema, also referred to as dermatitis, is an inflammatory condition of the skin. Atopic dermatitis and contact dermatitis are the most prevalent forms of eczema. It is a common skin condition affecting up to 7% of the population. Eczema can affect all ages from infants to adults. Eczema skin symptoms usually include redness, vesicles (tiny fluid filled bumps), dryness, mild swelling and most notably itching, which can be intense. As the condition progresses, the affected area can become crusty, scaly, and sometimes oozing.
CytoGenix scientists are developing a topical cream containing the company's proprietary ssDNA expression system engineered to express a sequence that silences a human gene associated with most inflammation.
The Company has scheduled initial preclinical studies to commence in 3rd quarter 2004.
I hope you know I was just joking around I like all you guys .Back to the science I think that our technology is branching out into to many areas ,to many thing going at once.I think we will be seeing a couple of new people shortly and not to replace LW and MS ,and a grant should be showing up shortly.
Actually its the three stooges and if you think of Arnold as MOE ,Suky as Larry ,and you Eightball as Curley, all three of you slapping each other in the head Yelling why did we sell so low, its very hilarious .Next episode Curley boils his shoe soles to eat remembering the day he owned CYGX.LOL
New poster nice to see you coincidently on the TV show green acres wasn't there a character name arnold we have one here .LOL
Hmmm the ones that agree are the ones who sold so they would like to get back in at the price they sold at ,I got it.
Holycow I second that .Cheers
Peace I agree to the non event but everthing after that no.
arnold actually it does mean that people are holding real hard ,and that this is really unheard of for a stock with this many shares out. This stock trades like a 2 million share float .And once all the day trading lemmings are out this will skyrock .Only the true longs will retire wealthy.